Camp4 Therapeutics Revenue Growth Rates (CAMP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Camp4 Therapeutics Corporation  (NASDAQ: CAMP)
 

CAMP's Revenue Growth by Quarter and Year

Camp4 Therapeutics's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CAMP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.78
1st Quarter March 1.29
FY 3.07

CAMPs Annual Revenue
Camp4 Therapeutics's Revenue in the fiscal year 2025 $ 3.50 millions
Camp4 Therapeutics's Revenue in the fiscal year 2024 $ 0.65 millions
Camp4 Therapeutics's Revenue in the fiscal year 2023 $ 294.95 millions
Camp4 Therapeutics's Revenue in the fiscal year 2022 $ 295.84 millions
Camp4 Therapeutics's Revenue in the fiscal year 2021 $ 308.59 millions




CAMP Revenue second quarter 2026 Y/Y Growth Comment
Camp4 Therapeutics Corporation achieved in the second quarter 2026, above Company average Revenue increase of 18.6% year on year, to $ 1.78 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Revenue growth. While Camp4 Therapeutics Corporation' s Revenue growth of 18.6% ranks overall at the positon no. 3069 in the second quarter 2026.


CAMP Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -46.15 % -98.79 % -32.1 %
3rd Quarter September - - - -15.78 %
2nd Quarter June 18.6 % - - 9.52 %
1st Quarter March 50 % - - 14.81 %
FY   - 440 % -99.75 % -

Financial Statements
Camp4 Therapeutics's second quarter 2026 Revenue $ 1.78 millions CAMP's Income Statement
Camp4 Therapeutics's second quarter 2025 Revenue $ 1.50 millions Quarterly CAMP's Income Statement


CAMP Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -56.25 % - -12.67 %
3rd Quarter September - -46.67 % - -13.47 %
2nd Quarter June 37.91 % 74.42 % - -9.71 %
1st Quarter March 268.57 % 32.31 % - -0.48 %
FY (Year on Year)   - 440 % -99.75 % -


Back to CAMP Growth rate Comparisons >> Back to CAMP Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #419
Overall #3069

Revenue Y/Y Growth Statistics
High Average Low
30.64 % 4.36 % -16.13 %
(Feb 28 2014)   (Nov 30 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #419
Overall #3069
Revenue Y/Y Growth Statistics
High Average Low
30.64 % 4.36 % -16.13 %
(Feb 28 2014)   (Nov 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Camp4 Therapeutics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
271.84 % 2.73 % -100 %
(Mar 31 2026)  


CAMP's II. Quarter Q/Q Revenue Comment
Camp4 Therapeutics Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 37.91%, to $ 1.78 millions, from $1.29 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Camp4 Therapeutics's Revenue growth quarter on quarter, overall rank is 298.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #298
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #298
Revenue Q/Q Growth Statistics
High Average Low
271.84 % 2.73 % -100 %
(Mar 31 2026)  


CAMP's II. Quarter Q/Q Revenue Comment
Camp4 Therapeutics Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 37.91%, to $ 1.78 millions, from $1.29 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Camp4 Therapeutics's Revenue growth quarter on quarter, overall rank is 298.


Camp4 Therapeutics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4.22 $ 3.93 $ 3.50 $ 3.80 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 7.17 % 12.46 % -8 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 3143 # 2956 # 2733 # 0 # 2356


Cumulative Revenue growth Comment
Camp4 Therapeutics saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 18.6% year on year, to $ 4 millions if the fiscal year would have ended in Jun 30 2026.
Camp4 Therapeutics's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Camp4 Therapeutics realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 7.17 % from $3.93 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 4.36%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.17 % increase from $3.93 millions in the period from Mar 31 2026 to Jun 30 2025.

Camp4 Therapeutics Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 422
S&P 500 # 3143
Cumulative Revenue growth Comment
Camp4 Therapeutics saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 18.6% year on year, to $ 4 millions if the fiscal year would have ended in Jun 30 2026.
Camp4 Therapeutics's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Camp4 Therapeutics realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 7.17 % from $3.93 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 4.36%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.17 % increase from $3.93 millions in the period from Mar 31 2026 to Jun 30 2025.

Camp4 Therapeutics Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 422
S&P 500 # 3143




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CAMP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions


About Camp4 Therapeutics Revenue Growth Rates (CAMP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Calamp Corp (CIK 730255).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-003368
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Calamp Corp ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.